Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 28,058 |
Ending reported balance
After 2026-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-13 · Sale · Disposed 5,278 · Balance 30,331 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026. Row 2 · 2026-08-14 · Sale · Disposed 2,273 · Balance 28,058 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 20:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,273 | $57.15 | $129,901.95 |
DisclosureSEC source: 0001610717-26-000359 · form4.xml · nonDerivative · entry 2 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,058 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 20:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,278 | $57.29 | $302,376.62 |
DisclosureSEC source: 0001610717-26-000359 · form4.xml · nonDerivative · entry 1 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,331 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 23:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000196 · form4.xml · nonDerivative · entry 1 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,609 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,579 | $19.41 | $147,108.39 |
DisclosureSEC source: 0001610717-26-000074 · form4.xml · nonDerivative · entry 1 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,780 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 26, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 15,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000172 · form4.xml · nonDerivative · entry 1 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,359 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 19,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000461 · form4.xml · nonDerivative · entry 1 Teichmann Sarah A. · CIK 0002030916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,002 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the RSUs shall vest on November 21, 2025 and 1/12th of the RSUs shall vest on each quarterly anniversary thereafter for the following two years, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.